The mission of the University of Colorado Anschutz Medical Campus (CU AMC) Drug Discovery and Development Shared Resource (D3SR) is to provide expertise and infrastructure to facilitate drug discovery at different stages of the development pipeline, including assay development and validation, high-throughput screening (HTS) and image-based high-content screening (HCS) discovery, hit-to-lead validation and optimization, and in vitro and in vivo pharmacology including pharmacokinetics (PK) and pharmacodynamics (PD) as well as toxicology.
To accomplish our mission the D3SR facility consists of two arms: (1) drug discovery and hit-to-lead drug development, and (2) in vivo pharmacology. Arm 1 of the D3SR is directed by Dan LaBarbera, PhD, CU AMC Skaggs School of Pharmacy and Pharmaceutical Sciences (SSPPS); and Arm 2 is directed by Dan Gustafson, PhD, located at Colorado State University (CSU). The D3SR is the main research infrastructure formally affiliated with a new CU AMC Center for Drug Discovery (CDD) housed in the SSPPS, and the University of Colorado Cancer Center (CUCC). The D3SR supports drug discovery and development research for both the CDD and the CUCC affiliated members. In addition, the D3SR facility is an available resource for all academic, government, and industry researchers or institutions interested in drug discovery at CU AMC, in Colorado, throughout the United States, and Internationally.
If you use Cancer Center shared resources, be sure to acknowledge the Cancer Center Support Grant (P30CA046934) and submit your publications to PubMed Central. Thank you!